S1937
|
SWOG
|
A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
|
Adult CIRB - Late Phase Emphasis
|
S2000
|
SWOG
|
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
|
Adult CIRB - Late Phase Emphasis
|
S2001
|
SWOG
|
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
|
Adult CIRB - Late Phase Emphasis
|
S2005
|
SWOG
|
A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
|
Adult CIRB - Late Phase Emphasis
|
S2007
|
SWOG
|
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
|
Adult CIRB - Late Phase Emphasis
|
S2010
|
SWOG
|
A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (Aspen)
|
Cancer Prevention and Control CIRB
|
S2011
|
SWOG
|
Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP Trial
|
Adult CIRB - Late Phase Emphasis
|
S2012
|
SWOG
|
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
|
Adult CIRB - Late Phase Emphasis
|
S2013
|
SWOG
|
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
|
Cancer Prevention and Control CIRB
|
S2015
|
SWOG
|
Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
|
Adult CIRB - Late Phase Emphasis
|